Eupraxia Pharmaceuticals Unveils Promising Data from EP-104GI Trial for Eosinophilic Esophagitis#Canada#Victoria#Eosinophilic_Esophagitis#Eupraxia_Pharmaceuticals#EP-104GI
Eupraxia Pharmaceuticals Unveils Promising Data from EP-104GI Trial for Eosinophilic Esophagitis
Eupraxia Pharmaceuticals shares encouraging results from the RESOLVE trial for EP-104GI, indicating significant improvements in treating Eosinophilic Esophagitis symptoms and safety.
third-news.com
February 25, 2025 at 12:24 PM
Eupraxia Pharmaceuticals Unveils Promising Data from EP-104GI Trial for Eosinophilic Esophagitis#Canada#Victoria#Eosinophilic_Esophagitis#Eupraxia_Pharmaceuticals#EP-104GI
Eupraxia Pharmaceuticals Announces Transition in CFO Role for Strategic Leadership#Canada#Victoria#Eupraxia_Pharmaceuticals#Alex_Rothwell#Bruce_Cousins
Eupraxia Pharmaceuticals Announces Transition in CFO Role for Strategic Leadership
Eupraxia Pharmaceuticals announces Alex Rothwell as new CFO, succeeding Bruce Cousins. This transition aims to leverage Rothwell’s expertise for future growth.
third-news.com
February 18, 2025 at 12:08 PM
Eupraxia Pharmaceuticals Announces Transition in CFO Role for Strategic Leadership#Canada#Victoria#Eupraxia_Pharmaceuticals#Alex_Rothwell#Bruce_Cousins